Treatment of Sarcoidosis

Marlies S Wijsenbeek; Daniel A Culver

doi:10.1016/j.ccm.2015.08.015

Treatment of Sarcoidosis

Clin Chest Med. 2015 Dec;36(4):751-67. doi: 10.1016/j.ccm.2015.08.015.

Authors

Marlies S Wijsenbeek¹, Daniel A Culver²

Affiliations

¹ Department of Pulmonary Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
² Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA; Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Electronic address: culverd@ccf.org.

PMID: 26593147
DOI: 10.1016/j.ccm.2015.08.015

Abstract

Treatment of sarcoidosis is not required in all patients with the diagnosis. The decision to treat and the strategy for how to treat usually require input and shared decision making by the patient. Some common consequences of sarcoidosis are not caused by granulomatous inflammation, but may be the dominant disease manifestation and should be actively considered when formulating a treatment plan. The medication regimen should be tailored to each patient. Steroid-sparing medications should be prescribed early as part of a long-term strategy.

Keywords: Corticosteroids; Patient preferences; Prognosis; Sarcoidosis; Steroid sparing; TNF antagonists; Treatment.

Publication types

Review

MeSH terms

Humans
Inflammation / therapy*
Prognosis
Sarcoidosis / therapy*